ciltacabtagene autoleucel,Pomalidomide,Bortezomib,Dexamethasone,Daratumumab
Janssen
['lenalidomide', ' lena', 'cartitude', 'cilta-cel', 'cartitude-4']
dr hermann einsele summarises the results of the clinical trial cartitude-4, presented at #eha2023. this trial evaluates the car-t treatment cilta-cel versus standard of care (pvd or dpd) in lenalidomide-refractory myeloma patients. 
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe